Top

27-02-2024 | Hepatocellular Carcinoma | REVIEW

Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma

Authors: Ghazaal Roozitalab, Behnaz Abedi, Saber Imani, Reyhaneh Farghadani, Parham Jabbarzadeh Kaboli

Published in: Cancer and Metastasis Reviews

Abstract

Atezolizumab (TECENTRIQ®) and nivolumab (OPDIVO®) are both immunotherapeutic indications targeting programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 (PD-1), respectively. These inhibitors hold promise as therapies for triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC) and have demonstrated encouraging results in reducing the progression and spread of tumors. However, due to their adverse effects and low response rates, the US Food and Drug Administration (FDA) has withdrawn the approval of atezolizumab in TNBC and nivolumab in HCC treatment. The withdrawals of atezolizumab and nivolumab have raised concerns regarding their effectiveness and the ability to predict treatment responses. Therefore, the current study aims to investigate the immunotherapy withdrawal of PD-1/PD-L1 inhibitors, specifically atezolizumab for TNBC and nivolumab for HCC. This study will examine both the structural and clinical aspects. This review provides detailed insights into the structure of the PD-1 receptor and its ligands, the interactions between PD-1 and PD-L1, and their interactions with the withdrawn antibodies (atezolizumab and nivolumab) as well as PD-1 and PD-L1 modifications. In addition, this review further assesses these antibodies in the context of TNBC and HCC. It seeks to elucidate the factors that contribute to diverse responses to PD-1/PD-L1 therapy in different types of cancer and propose approaches for predicting responses, mitigating the potential risks linked to therapy withdrawals, and optimizing patient outcomes. By better understanding the mechanisms underlying responses to PD-1/PD-L1 therapy and developing strategies to predict these responses, it is possible to create more efficient treatments for TNBC and HCC.

Graphical Abstract

Available only for authorised users

Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020). Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Journal of hepatology, 72(2), 320–341. https://doi.org/10.1016/j.jhep.2019.10.021CrossRefPubMedPubMedCentral

Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Frontiers in Pharmacology, 8, 561. https://doi.org/10.3389/fphar.2017.00561CrossRefPubMedPubMedCentral

Okusaka, T., & Ikeda, M. (2018). Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. ESMO open, 3(Suppl 1), e000455. https://doi.org/10.1136/esmoopen-2018-000455CrossRefPubMedPubMedCentral

Jabbarzadeh Kaboli, P., Shabani, S., Sharma, S., Partovi Nasr, M., Yamaguchi, H., & Hung, M.-C. (2022). Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. American Journal of Cancer Research, 12(4), 1671–1685.PubMedPubMedCentral

Patil, N. S., Nabet, B. Y., Müller, S., Koeppen, H., Zou, W., Giltnane, J., …Shames, D. S. (2022). Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell, 40(3), 289−300.e4. https://doi.org/10.1016/j.ccell.2022.02.002

Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., …Wang, S. (2022). The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology, 13, 964442. https://doi.org/10.3389/fimmu.2022.964442

Jiang, H., Ni, H., Zhang, P., Guo, X., Wu, M., Shen, H., …Liu, J. (2021). PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology, 10(1), 1943180. https://doi.org/10.1080/2162402X.2021.1943180

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., …Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for Immunotherapy of Cancer, 10(8). https://doi.org/10.1136/jitc-2022-005147

Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., …Diaz, L. A. J. (2022). PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. The New England Journal of Medicine, 386(25), 2363–2376. https://doi.org/10.1056/NEJMoa2201445

10.

Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2021). Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: A systematic review and Bayesian network meta-analysis. Journal of Cancer, 12(4), 1133–1143. https://doi.org/10.7150/jca.49325CrossRefPubMedPubMedCentral

11.

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., …Hodi, F. S. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 515(7528), 563–567. https://doi.org/10.1038/nature14011

12.

Weinstock, C., Khozin, S., Suzman, D., Zhang, L., Tang, S., Wahby, S., …Pazdur, R. (2017). U.S. food and drug administration approval summary: Atezolizumab for metastatic non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(16), 4534–4539. https://doi.org/10.1158/1078-0432.CCR-17-0540

13.

Ribeiro, R., Carvalho, M. J., Goncalves, J., & Moreira, J. N. (2022). Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. Frontiers in Molecular Biosciences, 9, 903065. https://doi.org/10.3389/fmolb.2022.903065CrossRefPubMedPubMedCentral

14.

Emens, L. A., Adams, S., Cimino-Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., …Litton, J. K. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for Immunotherapy of Cancer, 9(8). https://doi.org/10.1136/jitc-2021-002597

15.

Faivre, S., Rimassa, L., & Finn, R. S. (2020). Molecular therapies for HCC: Looking outside the box. Journal of Hepatology, 72(2), 342–352. https://doi.org/10.1016/j.jhep.2019.09.010CrossRefPubMed

16.

Jin, H., Qin, S., He, J., Xiao, J., Li, Q., Mao, Y., & Zhao, L. (2022). New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: From mechanisms to clinical trials. International Journal of Biological Sciences, 18(7), 2775–2794. https://doi.org/10.7150/ijbs.70691CrossRefPubMedPubMedCentral

17.

Feng, D., Hui, X., Shi-Chun, L., Yan-Hua, B., Li, C., Xiao-Hui, L., & Jie-Yu, Y. (2017). Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget, 8(57), 96649–96655. https://doi.org/10.18632/oncotarget.20029CrossRefPubMedPubMedCentral

18.

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., …Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England), 389(10088), 2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2

19.

Bally, A. P. R., Austin, J. W., & Boss, J. M. (2016). Genetic and epigenetic regulation of PD-1 expression. Journal of immunology (Baltimore, Md. : 1950), 196(6), 2431–2437. https://doi.org/10.4049/jimmunol.1502643CrossRefPubMed

20.

Liu, W., Jin, H., Chen, T., Zhang, G., Lai, S., & Liu, G. (2020). Investigating the role of the N-Terminal Loop of PD-1 in binding process between PD-1 and nivolumab via molecular dynamics simulation. Frontiers in Molecular Biosciences, 7, 574759. https://doi.org/10.3389/fmolb.2020.574759CrossRefPubMedPubMedCentral

21.

Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., …Holak, T. A. (2015). Structure of the complex of human programmed death 1, PD-1, and Its Ligand PD-L1. Structure (London, England : 1993), 23(12), 2341–2348. https://doi.org/10.1016/j.str.2015.09.010

22.

Chen, D., Tan, S., Zhang, H., Wang, H., He, W., Shi, R., …Gao, G. F. (2019). The FG loop of PD-1 serves as a “Hotspot” for therapeutic monoclonal antibodies in tumor immune checkpoint therapy. iScience, 14, 113–124. https://doi.org/10.1016/j.isci.2019.03.017

23.

Qi, T., Fu, J., Zhang, W., Cui, W., Xu, X., Yue, J., …Tian, X. (2020). Mutation of PD-1 immune receptor tyrosine-based switch motif (ITSM) enhances the antitumor activity of cytotoxic T cells. Translational Cancer Research, 9(11), 6811–6819. https://doi.org/10.21037/tcr-20-2118

24.

Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., …Boussiotis, V. A. (2020). Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Communications Biology, 3(1), 128. https://doi.org/10.1038/s42003-020-0845-0

25.

Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G., & Almo, S. C. (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10483–10488. https://doi.org/10.1073/pnas.0804453105ADSCrossRefPubMedPubMedCentral

26.

Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994). Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics, 23(3), 704–706. https://doi.org/10.1006/geno.1994.1562CrossRefPubMed

27.

Zhao, Q., Guo, J., Zhao, Y., Shen, J., Kaboli, P. J., Xiang, S., …Xiao, Z. (2020). Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers. Epigenomics, 12(24), 2155–2171. https://doi.org/10.2217/epi-2020-0093

28.

Li, D., Xiang, S., Shen, J., Xiao, M., Zhao, Y., Wu, X., …Wen, Q. (2020). Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets. International Journal of Biological Sciences, 16(4), 568–582. https://doi.org/10.7150/ijbs.39769

29.

Wang, H., Yao, H., Li, C., Shi, H., Lan, J., Li, Z., …Xu, J. (2019). HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nature Chemical Biology, 15(1), 42–50. https://doi.org/10.1038/s41589-018-0161-x

30.

Chen, Y., Liu, P., Gao, F., Cheng, H., Qi, J., & Gao, G. F. (2010). A dimeric structure of PD-L1: Functional units or evolutionary relics? Protein Cell, 1(2), 153–160. https://doi.org/10.1007/s13238-010-0022-1CrossRefPubMedPubMedCentral

31.

Okazaki, T., & Honjo, T. (2006). The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology, 27(4), 195–201. https://doi.org/10.1016/j.it.2006.02.001CrossRefPubMed

32.

Philips, E. A., Garcia-España, A., Tocheva, A. S., Ahearn, I. M., Adam, K. R., Pan, R., …Kong, X.-P. (2020). The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. The Journal of Biological Chemistry, 295(14), 4372–4380. https://doi.org/10.1074/jbc.AC119.011747

33.

Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003). Molecular modeling and functional mapping of B7–H1 and B7-DC uncouple costimulatory function from PD-1 interaction. The Journal of Experimental Medicine, 197(9), 1083–1091. https://doi.org/10.1084/jem.20021752CrossRefPubMedPubMedCentral

34.

Gainza, P., Wehrle, S., VanHall-Beauvais, A., Marchand, A., Scheck, A., Harteveld, Z., …Correia, B. E. (2023). De novo design of protein interactions with learned surface fingerprints. Nature, 617(7959), 176–184. https://doi.org/10.1038/s41586-023-05993-x

35.

Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., …Garboczi, D. N. (2008). The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3011–3016. https://doi.org/10.1073/pnas.0712278105

36.

Almahmoud, S., & Zhong, H. A. (2019). Molecular modeling studies on the binding mode of the PD-1/PD-L1 complex inhibitors. International Journal of Molecular Sciences, 20(18). https://doi.org/10.3390/ijms20184654

37.

Lee, H. T., Lee, J. Y., Lim, H., Lee, S. H., Moon, Y. J., Pyo, H. J., …Heo, Y.-S. (2017). Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific Reports, 7(1), 5532. https://doi.org/10.1038/s41598-017-06002-8

38.

Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., …Yan, J. (2017). An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 8, 14369. https://doi.org/10.1038/ncomms14369

39.

Hao, G., Wesolowski, J. S., Jiang, X., Lauder, S., & Sood, V. D. (2015). Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches. Journal of Molecular Recognition: JMR, 28(4), 269–276. https://doi.org/10.1002/jmr.2418CrossRefPubMed

40.

Magarkar, A., Schnapp, G., Apel, A.-K., Seeliger, D., & Tautermann, C. S. (2019). Enhancing drug residence time by shielding of intra-protein hydrogen bonds: A case study on CCR2 antagonists. ACS Medicinal Chemistry Letters, 10(3), 324–328. https://doi.org/10.1021/acsmedchemlett.8b00590CrossRefPubMedPubMedCentral

41.

Lee, J. Y., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., …Heo, Y.-S. (2016). Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nature Communications, 7, 13354. https://doi.org/10.1038/ncomms13354

42.

Bangarh, R., Khatana, C., Kaur, S., Sharma, A., Kaushal, A., Siwal, S. S., …Saini, A. K. (2023). Aberrant protein glycosylation: Implications on diagnosis and Immunotherapy. Biotechnology Advances, 66, 108149. https://doi.org/10.1016/j.biotechadv.2023.108149

43.

Hu, M., Zhang, R., Yang, J., Zhao, C., Liu, W., Huang, Y., …Tang, J. (2023). The role of N-glycosylation modification in the pathogenesis of liver cancer. Cell Death & Disease, 14(3), 222. https://doi.org/10.1038/s41419-023-05733-z

44.

Liu, Y., Lan, L., Li, Y., Lu, J., He, L., Deng, Y., …Lu, B. (2022). N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth. Redox Biology, 54, 102366. https://doi.org/10.1016/j.redox.2022.102366

45.

Morales-Betanzos, C. A., Lee, H., Gonzalez Ericsson, P. I., Balko, J. M., Johnson, D. B., Zimmerman, L. J., & Liebler, D. C. (2017). Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Molecular & Cellular Proteomics: MCP, 16(10), 1705–1717. https://doi.org/10.1074/mcp.RA117.000037CrossRefPubMedCentral

46.

D’Arrigo, P., Russo, M., Rea, A., Tufano, M., Guadagno, E., DelBasso De Caro, M. L., …Romano, S. (2017). A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget, 8(40), 68291–68304. https://doi.org/10.18632/oncotarget.19309

47.

Maher, C. M., Thomas, J. D., Haas, D. A., Longen, C. G., Oyer, H. M., Tong, J. Y., & Kim, F. J. (2018). Small-Molecule Sigma1 modulator induces autophagic degradation of PD-L1. Molecular Cancer Research: MCR, 16(2), 243–255. https://doi.org/10.1158/1541-7786.MCR-17-0166CrossRefPubMed

48.

Duan, X., Xie, Y., Yu, J., Hu, X., Liu, Z., Li, N., …Wang, Y. (2022). MCT4/Lactate promotes PD-L1 glycosylation in triple-negative breast cancer cells. Journal of Oncology, 2022, 3659714. https://doi.org/10.1155/2022/3659714

49.

Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., …Hung, M.-C. (2016). Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications, 7, 12632. https://doi.org/10.1038/ncomms12632

50.

Ou-Yang, F., Li, C.-L., Chen, C.-C., Shen, Y.-C., Moi, S.-H., Luo, C.-W., …Hung, M.-C. (2022). De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients. American Journal of Cancer Research, 12(1), 123–137

51.

Goletz, C., Lischke, T., Harnack, U., Schiele, P., Danielczyk, A., Rühmann, J., & Goletz, S. (2018). Glyco-engineered anti-human programmed death-Ligand 1 antibody mediates stronger CD8 T cell activation than its normal glycosylated and non-glycosylated counterparts. Frontiers in Immunology, 9, 1614. https://doi.org/10.3389/fimmu.2018.01614CrossRefPubMedPubMedCentral

52.

Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., …Dahan, R. (2023). Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Science Immunology, 8(81), eadd8005. https://doi.org/10.1126/sciimmunol.add8005

53.

Okada, M., Chikuma, S., Kondo, T., Hibino, S., Machiyama, H., Yokosuka, T., …Yoshimura, A. (2017). Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells. Cell Reports, 20(5), 1017–1028. https://doi.org/10.1016/j.celrep.2017.07.027

54.

Sun, L., Li, C.-W., Chung, E. M., Yang, R., Kim, Y.-S., Park, A. H., …Hung, M.-C. (2020). Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Research, 80(11), 2298–2310. https://doi.org/10.1158/0008-5472.CAN-19-3133

55.

Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., …Cheng, X. (2022). Anti-tumour potential of PD-L1/PD-1 post-translational modifications. Immunology, 167(4), 471–481. https://doi.org/10.1111/imm.13573

56.

Wang, M., Wang, J., Wang, R., Jiao, S., Wang, S., Zhang, J., & Zhang, M. (2019). Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Communications Biology, 2, 392. https://doi.org/10.1038/s42003-019-0642-9CrossRefPubMedPubMedCentral

57.

Bristol Myers Squibb Co. (2014). Nivolumab (Opdivo). drugs@FDA. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000PharmR.pdf

58.

Huang, Z., Pang, X., Zhong, T., Qu, T., Chen, N., Ma, S., …Li, B. (2022). Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events. Frontiers in Immunology, 13, 924542. https://doi.org/10.3389/fimmu.2022.924542

59.

Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., …Hung, M.-C. (2018). Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Molecular Cell, 71(4), 606–620.e7. https://doi.org/10.1016/j.molcel.2018.07.030

60.

Dai, X., Bu, X., Gao, Y., Guo, J., Hu, J., Jiang, C., …Wei, W. (2021). Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular Cell, 81(11), 2317–2331.e6. https://doi.org/10.1016/j.molcel.2021.03.037

61.

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., deVries, E., Wu, W., …Schumacher, T. N. M. (2017). Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 549(7670), 106–110. https://doi.org/10.1038/nature23669

62.

Chan, L.-C., Li, C.-W., Xia, W., Hsu, J.-M., Lee, H.-H., Cha, J.-H., …Hung, M.-C. (2019). IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. The Journal of Clinical Investigation, 129(8), 3324–3338. https://doi.org/10.1172/JCI126022

63.

Zhang, X., Huang, X., Xu, J., Li, E., Lao, M., Tang, T., …Liang, T. (2021). NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nature Communications, 12(1), 4536. https://doi.org/10.1038/s41467-021-24769-3

64.

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of experimental medicine, 209(6), 1201–1217. https://doi.org/10.1084/jem.20112741CrossRefPubMedPubMedCentral

65.

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., …Vale, R. D. (2017). T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science, 4(March), eaaf1292. https://doi.org/10.1126/science.aaf1292

66.

Fernandes, R. A., Su, L., Nishiga, Y., Ren, J., Bhuiyan, A. M., Cheng, N., …Garcia, K. C. (2020). Immune receptor inhibition through enforced phosphatase recruitment. Nature, 586(7831), 779–784. https://doi.org/10.1038/s41586-020-2851-2

67.

Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., …Carlomagno, T. (2020). Molecular mechanism of SHP2 activation by PD-1 stimulation. Science Advances, 6(5), eaay4458. https://doi.org/10.1126/sciadv.aay4458

68.

Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., …Chen, L. (2020). Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO Molecular Medicine, 12(6), e11571. https://doi.org/10.15252/emmm.201911571

69.

Bu, X., Juneja, V. R., Reynolds, C. G., Mahoney, K. M., Bu, M. T., McGuire, K. A., …Freeman, G. J. (2021). Monitoring PD-1 phosphorylation to evaluate PD-1 signaling during antitumor immune responses. Cancer Immunology Research, 9(12), 1465–1475. https://doi.org/10.1158/2326-6066.CIR-21-0493

70.

Dai, X., Gao, Y., & Wei, W. (2022). Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. Seminars in Cancer Biology, 85, 246–252. https://doi.org/10.1016/j.semcancer.2021.04.002CrossRefPubMed

71.

Yang, Z., Wang, Y., Liu, S., Deng, W., Lomeli, S. H., Moriceau, G., …Lo, R. S. (2022). Enhancing PD-L1 degradation by ITCH during MAPK inhibitor therapy suppresses acquired resistance. Cancer Discovery, 12(8), 1942–1959. https://doi.org/10.1158/2159-8290.CD-21-1463

72.

Wu, Y., Zhang, C., Liu, X., He, Z., Shan, B., Zeng, Q., …Xia, H. (2021). ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nature Communications, 12(1), 2346. https://doi.org/10.1038/s41467-021-22467-8

73.

Qian, G., Guo, J., Vallega, K. A., Hu, C., Chen, Z., Deng, Y., …Sun, S.-Y. (2021). Membrane-associated RING-CH 8 functions as a Novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. Molecular Cancer Research : MCR, 19(10), 1622–1634. https://doi.org/10.1158/1541-7786.MCR-21-0147

74.

Gao, K., Shi, Q., Gu, Y., Yang, W., He, Y., Lv, Z., …Wan, X. (2023). SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell Death and Differentiation, 30(2), 475–487. https://doi.org/10.1038/s41418-022-01097-7

75.

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., …Wei, W. (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature, 553(7686), 91–95. https://doi.org/10.1038/nature25015

76.

Gao, L., Xia, L., Ji, W., Zhang, Y., Xia, W., & Lu, S. (2021). Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma. Translational Oncology, 14(9), 101148. https://doi.org/10.1016/j.tranon.2021.101148CrossRefPubMedPubMedCentral

77.

De, S., Holvey-Bates, E. G., Mahen, K., Willard, B., &Stark, G. R. (2021). The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 118(47). https://doi.org/10.1073/pnas.2112674118

78.

Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., …Petrosiute, A. (2016). Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science, 353(6297), 399–403. https://doi.org/10.1126/science.aae0477

79.

Meng, X., Liu, X., Guo, X., Jiang, S., Chen, T., Hu, Z., …Xu, C. (2018). FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature, 564(7734), 130–135. https://doi.org/10.1038/s41586-018-0756-0

80.

Zhong, B., Zheng, J., Wen, H., Liao, X., Chen, X., Rao, Y., & Yuan, P. (2022). NEDD4L suppresses PD-L1 expression and enhances anti-tumor immune response in A549 cells. Genes & Genomics, 44(9), 1071–1079. https://doi.org/10.1007/s13258-022-01238-9CrossRef

81.

Zhou, X. A., Zhou, J., Zhao, L., Yu, G., Zhan, J., Shi, C., …Wang, J. (2020). KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proceedings of the National Academy of Sciences of the United States of America, 117(45), 28239–28250. https://doi.org/10.1073/pnas.2004570117

82.

Sharma, N., Ponce, M., Kaul, S., Pan, Z., Berry, D. M., Eiwegger, T., & McGlade, C. J. (2019). SLAP Is a negative regulator of FcεRI receptor-mediated signaling and allergic response. Frontiers in Immunology, 10, 1020. https://doi.org/10.3389/fimmu.2019.01020CrossRefPubMedPubMedCentral

83.

Tang, R., Langdon, W. Y., & Zhang, J. (2022). Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases. Frontiers in Endocrinology, 13, 971162. https://doi.org/10.3389/fendo.2022.971162CrossRefPubMedPubMedCentral

84.

Lyle, C., Richards, S., Yasuda, K., Napoleon, M. A., Walker, J., Arinze, N., …Chitalia, V. C. (2019). c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Scientific Reports, 9(1), 20257. https://doi.org/10.1038/s41598-019-56208-1

85.

Qin, R., Zhao, C., Wang, C.-J., Xu, W., Zhao, J.-Y., Lin, Y., …Huang, Y. (2021). Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. Journal for Immunotherapy of Cancer, 9(7). https://doi.org/10.1136/jitc-2021-002840

86.

Ichikawa, S., Flaxman, H. A., Xu, W., Vallavoju, N., Lloyd, H. C., Wang, B., …Woo, C. M. (2022). The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. Nature, 610(7933), 775–782. https://doi.org/10.1038/s41586-022-05333-5

87.

Ioannou, N., Hagner, P. R., Stokes, M., Gandhi, A. K., Apollonio, B., Fanous, M., …Ramsay, A. G. (2021). Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 137(2), 216–231. https://doi.org/10.1182/blood.2020006073

88.

Zou, J., Xia, H., Zhang, C., Xu, H., Tang, Q., Zhu, G., …Bi, F. (2021). Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. Cancer Science, 112(7), 2664–2678. https://doi.org/10.1111/cas.14932

89.

Shi, C., Wang, Y., Wu, M., Chen, Y., Liu, F., Shen, Z., …Lin, A. (2022). Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nature Communications, 13(1), 6951. https://doi.org/10.1038/s41467-022-34346-x

90.

Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., …Dawson, M. A. (2017). CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 549(7670), 101–105. https://doi.org/10.1038/nature23643

91.

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., …Izar, B. (2023). The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell, 41(7), 1207–1221.e12. https://doi.org/10.1016/j.ccell.2023.05.014

92.

Chen, S., Liu, Y., &Zhou, H. (2021). Advances in the development ubiquitin-specific peptidase (USP) inhibitors. International Journal of Molecular Sciences, 22(9). https://doi.org/10.3390/ijms22094546

93.

Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., …Liu, X. (2020). The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Communication and Signaling : CCS, 18(1), 112. https://doi.org/10.1186/s12964-020-00612-y

94.

Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., …Hung, M.-C. (2016). Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell, 30(6), 925–939. https://doi.org/10.1016/j.ccell.2016.10.010

95.

Jingjing, W., Wenzheng, G., Donghua, W., Guangyu, H., Aiping, Z., & Wenjuan, W. (2018). Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Medicine, 7(8), 4004–4011. https://doi.org/10.1002/cam4.1675CrossRefPubMedPubMedCentral

96.

Pan, J., Qiao, Y., Chen, C., Zang, H., Zhang, X., Qi, F., …Chen, G. (2021). USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1. Cell Death & Disease, 12(11), 1051. https://doi.org/10.1038/s41419-021-04356-6

97.

Yang, S., Yan, H., Wu, Y., Shan, B., Zhou, D., Liu, X., …Xia, H. (2021). Deubiquitination and Stabilization of PD-L1 by USP21. American Journal of Translational Research, 13(11), 12763–12774.

98.

Li, B., & Wang, B. (2022). USP7 enables immune escape of glioma cells by regulating PD-L1 expression. Immunological Investigations, 51(7), 1921–1937. https://doi.org/10.1080/08820139.2022.2083972CrossRefPubMed

99.

Wang, Z., Kang, W., Li, O., Qi, F., Wang, J., You, Y., …Liu, H.-M. (2021). Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica. B, 11(3), 694–707. https://doi.org/10.1016/j.apsb.2020.11.005

100.

Zhu, D., Xu, R., Huang, X., Tang, Z., Tian, Y., Zhang, J., & Zheng, X. (2021). Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death and Differentiation, 28(6), 1773–1789. https://doi.org/10.1038/s41418-020-00700-zCrossRefPubMed

101.

Saung, M. T., Pelosof, L., Casak, S., Donoghue, M., Lemery, S., Yuan, M., …Fashoyin-Aje, L. (2021). FDA approval summary: Nivolumab plus Ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with Sorafenib. The oncologist, 26(9), 797–806. https://doi.org/10.1002/onco.13819

102.

Sharmni Vishnu, K., Win, T. T., Aye, S. N., & Basavaraj, A. K. (2022). Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: A meta-analysis on their efficacy and safety. BMC Cancer, 22(1), 1139. https://doi.org/10.1186/s12885-022-10225-yCrossRefPubMedPubMedCentral

103.

Li, X., Warren, S., Pelekanou, V., Wali, V., Cesano, A., Liu, M., …Pusztai, L. (2019). Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. Journal for Immunotherapy of Cancer, 7(1), 88. https://doi.org/10.1186/s40425-019-0563-7

104.

Foulds, G. A., Vadakekolathu, J., Abdel-Fatah, T. M. A., Nagarajan, D., Reeder, S., Johnson, C., …McArdle, S. E. B. (2018). Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: Identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Frontiers in Immunology, 9, 2028. https://doi.org/10.3389/fimmu.2018.02028

105.

Axelrod, M. L., Nixon, M. J., Gonzalez-Ericsson, P. I., Bergman, R. E., Pilkinton, M. A., McDonnell, W. J., …Balko, J. M. (2020). Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(21), 5668–5681. https://doi.org/10.1158/1078-0432.CCR-19-3685

106.

Lu, Y., Zhao, Q., Liao, J.-Y., Song, E., Xia, Q., Pan, J., …Su, S. (2020). Complement signals determine opposite effects of B cells in chemotherapy-induced immunity. Cell, 180(6), 1081–1097.e24. https://doi.org/10.1016/j.cell.2020.02.015

107.

Shen, M., Wang, J., & Ren, X. (2018). New insights into tumor-infiltrating B lymphocytes in breast cancer: Clinical impacts and regulatory mechanisms. Frontiers in Immunology, 9, 470. https://doi.org/10.3389/fimmu.2018.00470CrossRefPubMedPubMedCentral

108.

Schumacher, T. N., & Thommen, D. S. (2022). Tertiary lymphoid structures in cancer. Science (New York, N.Y.), 375(6576), eabf9419. https://doi.org/10.1126/science.abf9419CrossRefPubMed

109.

Franzoi, M. A., Romano, E., & Piccart, M. (2021). Immunotherapy for early breast cancer: Too soon, too superficial, or just right? Annals of Oncology: Official journal of the European Society for Medical Oncology, 32(3), 323–336. https://doi.org/10.1016/j.annonc.2020.11.022CrossRefPubMed

110.

Wang, B., Liu, J., Han, Y., Deng, Y., Li, J., & Jiang, Y. (2022). The presence of tertiary lymphoid structures provides new insight into the clinicopathological features and prognosis of patients with breast cancer. Frontiers in Immunology, 13, 868155. https://doi.org/10.3389/fimmu.2022.868155CrossRefPubMedPubMedCentral

111.

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., …Jönsson, G. (2020). Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 577(7791), 561–565. https://doi.org/10.1038/s41586-019-1914-8

112.

Wang, Q., Sun, K., Liu, R., Song, Y., Lv, Y., Bi, P., …Tang, S. (2023). Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clinical and Translational Medicine, 13(8), e1346. https://doi.org/10.1002/ctm2.1346

113.

Sui, Q., Zhang, X., Chen, C., Tang, J., Yu, J., Li, W., …Ding, P.-R. (2022). Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nature Communications, 13(1), 7316. https://doi.org/10.1038/s41467-022-35096-6

114.

Liu, X., Xie, P., Hao, N., Zhang, M., Liu, Y., Liu, P., …Zhang, H. (2021). HIF-1-regulated expression of calreticulin promotes breast tumorigenesis and progression through Wnt/β-catenin pathway activation. Proceedings of the National Academy of Sciences of the United States of America, 118(44). https://doi.org/10.1073/pnas.2109144118

115.

Schütz, F., Stefanovic, S., Mayer, L., vonAu, A., Domschke, C., & Sohn, C. (2017). PD-1/PD-L1 pathway in breast cancer. Oncology research and treatment, 40(5), 294–297. https://doi.org/10.1159/000464353CrossRefPubMed

116.

Roux, C., Jafari, S. M., Shinde, R., Duncan, G., Cescon, D. W., Silvester, J., …Gorrini, C. (2019). Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America, 116(10), 4326–4335. https://doi.org/10.1073/pnas.1819473116

117.

Tan, Z., Chiu, M. S., Yang, X., Yue, M., Cheung, T. T., Zhou, D., …Chen, Z. (2023). Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut, 72(8), 1568–1580. https://doi.org/10.1136/gutjnl-2022-327133

118.

Li, S., Yu, J., Huber, A., Kryczek, I., Wang, Z., Jiang, L., …Zou, W. (2022). Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Reports, 39(1), 110609. https://doi.org/10.1016/j.celrep.2022.110609

119.

Gao, J., Liang, Y., & Wang, L. (2022). Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Frontiers in Immunology, 13, 888713. https://doi.org/10.3389/fimmu.2022.888713CrossRefPubMedPubMedCentral

120.

Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L. S., Ng, R. H., Leggett, N., …Priceman, S. J. (2022). PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. Journal for Immunotherapy of Cancer, 10(6). https://doi.org/10.1136/jitc-2021-004400

121.

Liu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., …Liu, L. (2023). Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of Hepatology, 78(4), 770–782. https://doi.org/10.1016/j.jhep.2023.01.011

122.

Stanczak, M. A., Rodrigues Mantuano, N., Kirchhammer, N., Sanin, D. E., Jacob, F., Coelho, R., …Läubli, H. (2022). Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science Translational Medicine, 14(669), eabj1270. https://doi.org/10.1126/scitranslmed.abj1270

123.

ElMeskini, R., Atkinson, D., Kulaga, A., Abdelmaksoud, A., Gumprecht, M., Pate, N., …Weaver Ohler, Z. (2021). Distinct biomarker profiles and TCR sequence diversity characterize the response to PD-L1 blockade in a mouse melanoma model. Molecular Cancer Research : MCR, 19(8), 1422–1436. https://doi.org/10.1158/1541-7786.MCR-20-0881

124.

Fehlings, M., Jhunjhunwala, S., Kowanetz, M., O’Gorman, W. E., Hegde, P. S., Sumatoh, H., …Yadav, M. (2019). Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. Journal for Immunotherapy of Cancer, 7(1), 249. https://doi.org/10.1186/s40425-019-0695-9

125.

Fehlings, M., Kim, L., Guan, X., Yuen, K., Tafazzol, A., Sanjabi, S., …Yadav, M. (2022). Single-cell analysis reveals clonally expanded tumor-associated CD57(+) CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. Journal for Immunotherapy of Cancer, 10(8). https://doi.org/10.1136/jitc-2022-004759

126.

Fameli, A., Nardone, V., Shekarkar Azgomi, M., Bianco, G., Gandolfo, C., Oliva, B. M., …Correale, P. (2022). PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach. Frontiers in Oncology, 12, 911579. https://doi.org/10.3389/fonc.2022.911579

127.

Park, J.-E., Kim, S.-E., Keam, B., Park, H.-R., Kim, S., Kim, M., …Heo, D. S. (2020). Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-000873

128.

Gopal, S., Kwon, S.-J., Ku, B., Lee, D. W., Kim, J., & Dordick, J. S. (2021). 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. Communications Biology, 4(1), 893. https://doi.org/10.1038/s42003-021-02417-2CrossRefPubMedPubMedCentral

129.

Hirosaki, H., Maeda, Y., & Takeyoshi, M. (2023). Establishment of cell-based assay system for evaluating cytotoxic activity modulated by the blockade of PD-1 and PD-L1 interactions with a therapeutic antibody. Immunological Investigations, 52(3), 332–342. https://doi.org/10.1080/08820139.2023.2174442CrossRefPubMed

130.

Hamdan, F., Ylösmäki, E., Chiaro, J., Giannoula, Y., Long, M., Fusciello, M., …Cerullo, V. (2021). Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Journal for Immunotherapy of Cancer, 9(8). https://doi.org/10.1136/jitc-2021-003000

131.

Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., …Rimm, D. L. (2020). Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(4), 970–977. https://doi.org/10.1158/1078-0432.CCR-19-1040

132.

Lin, H., Fu, L., Li, P., Zhu, J., Xu, Q., Wang, Y., …Cao, J. (2023). Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma. Journal of Translational Medicine, 21(1), 343. https://doi.org/10.1186/s12967-023-04161-z

133.

Xu, P., Yang, J. C., Chen, B., Nip, C., VanDyke, J. E., Zhang, X., …Liu, C. (2023). Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for Immunotherapy of Cancer, 11(5). https://doi.org/10.1136/jitc-2022-006581

134.

Yoshida, T., Ohe, C., Ito, K., Takada, H., Saito, R., Kita, Y., …Kobayashi, T. (2022). Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis. Cancer Immunology, Immunotherapy : CII, 71(11), 2815–2828. https://doi.org/10.1007/s00262-022-03204-6

135.

Emens, L. A., Molinero, L., Loi, S., Rugo, H. S., Schneeweiss, A., Diéras, V., …Schmid, P. (2021). Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the IMpassion130 study. Journal of the National Cancer Institute, 113(8), 1005–1016. https://doi.org/10.1093/jnci/djab004

136.

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., …Emens, L. A. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. The New England Journal of Medicine, 379(22), 2108–2121. https://doi.org/10.1056/NEJMoa1809615

137.

Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., …Schmid, P. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(8), 983–993. https://doi.org/10.1016/j.annonc.2021.05.355

138.

Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., …Emens, L. A. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21(1), 44–59. https://doi.org/10.1016/S1470-2045(19)30689-8

139.

Cortés, J., André, F., Gonçalves, A., Kümmel, S., Martín, M., Schmid, P., …Dent, R. (2019). IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 15(17), 1951–1961. https://doi.org/10.2217/fon-2019-0059

140.

Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., …O’Shaughnessy, J. (2021). Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(8), 994–1004. https://doi.org/10.1016/j.annonc.2021.05.801

141.

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., vonPawel, J., …Gandara, D. R. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England), 389(10066), 255–265. https://doi.org/10.1016/S0140-6736(16)32517-X

142.

vonPawel, J., Bordoni, R., Satouchi, M., Fehrenbacher, L., Cobo, M., Han, J. Y., …Park, K. (2019). Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European Journal of Cancer (Oxford, England : 1990), 107, 124–132. https://doi.org/10.1016/j.ejca.2018.11.020

143.

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., …Reck, M. (2018). Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. The New England Journal of Medicine, 378(24), 2288–2301. https://doi.org/10.1056/NEJMoa1716948

144.

Nogami, N., Barlesi, F., Socinski, M. A., Reck, M., Thomas, C. A., Cappuzzo, F., …Nishio, M. (2022). IMpower150 final exploratory analyses for Atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 17(2), 309–323. https://doi.org/10.1016/j.jtho.2021.09.014

145.

Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., …Sangro, B. (2021). CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology, 75(3), 600–609. https://doi.org/10.1016/j.jhep.2021.04.047

146.

Yau, T., Hsu, C., Kim, T.-Y., Choo, S.-P., Kang, Y.-K., Hou, M.-M., …Kudo, M. (2019). Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 71(3), 543–552. https://doi.org/10.1016/j.jhep.2019.05.014

147.

Sové, R. J., Verma, B. K., Wang, H., Ho, W. J., Yarchoan, M., & Popel, A. S. (2022). Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. Journal for Immunotherapy of Cancer, 10(11). https://doi.org/10.1136/jitc-2022-005414

148.

Yau, T., Zagonel, V., Santoro, A., Acosta-Rivera, M., Choo, S. P., Matilla, A., …Piscaglia, F. (2023). Nivolumab plus Cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: Results from cohort 6 of the CheckMate 040 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(9), 1747–1757. https://doi.org/10.1200/JCO.22.00972

149.

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., …Finn, R. S. (2022). Immunotherapies for hepatocellular carcinoma. Nature Reviews. Clinical Oncology, 19(3), 151–172. https://doi.org/10.1038/s41571-021-00573-2

150.

Aoki, H., Matsumoto, N., Takahashi, H., Honda, M., Kaneko, T., Arima, S., …Miura, K. (2021). Immune checkpoint inhibitor as a therapeutic choice for double cancer: A case series. Anticancer Research, 41(12), 6225–6230. https://doi.org/10.21873/anticanres.15442

151.

Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., …El-Khoueiry, A. (2020). Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 73(6), 1460–1469. https://doi.org/10.1016/j.jhep.2020.07.026

152.

Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., …Hsu, C. (2020). Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncology, 6(11), e204564. https://doi.org/10.1001/jamaoncol.2020.4564

153.

Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., …Sangro, B. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology, 23(1), 77–90. https://doi.org/10.1016/S1470-2045(21)00604-5

154.

Marcum, Z. A., VandeGriend, J. P., & Linnebur, S. A. (2012). FDA drug safety communications: A narrative review and clinical considerations for older adults. The American Journal of Geriatric Pharmacotherapy, 10(4), 264–271. https://doi.org/10.1016/j.amjopharm.2012.05.002CrossRefPubMedPubMedCentral

155.

Davda, J., Declerck, P., Hu-Lieskovan, S., Hickling, T. P., Jacobs, I. A., Chou, J., …Kraynov, E. (2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Journal for Immunotherapy of Cancer, 7(1), 105. https://doi.org/10.1186/s40425-019-0586-0

156.

Agrawal, S., Statkevich, P., Bajaj, G., Feng, Y., Saeger, S., Desai, D. D., …Gupta, M. (2017). Evaluation of immunogenicity of Nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. Journal of Clinical Pharmacology, 57(3), 394–400. https://doi.org/10.1002/jcph.818

157.

Wu, B., Sternheim, N., Agarwal, P., Suchomel, J., Vadhavkar, S., Bruno, R., …Quarmby, V. (2022). Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clinical and Translational Science, 15(1), 130–140. https://doi.org/10.1111/cts.13127

158.

Hammer, C., Ruppel, J., Kamen, L., Hunkapiller, J., Mellman, I., & Quarmby, V. (2022). Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro. Clinical and Translational Science, 15(6), 1393–1399. https://doi.org/10.1111/cts.13264CrossRefPubMedPubMedCentral

159.

Li, M., Zhao, R., Chen, J., Tian, W., Xia, C., Liu, X., …Sun, L. (2021). Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo. Scientific Reports, 11(1), 5774. https://doi.org/10.1038/s41598-021-85329-9

160.

Ha, J. Y., Chun, K.-J., Ko, S., Lee, H. W., Hwang, O. K., Lim, C. S., …Jung, S. T. (2023). Glycan-controlled human PD-1 variants displaying broad-spectrum high binding to PD-1 ligands potentiate T cell. Molecular Pharmaceutics, 20(4), 2170–2180. https://doi.org/10.1021/acs.molpharmaceut.3c00003

161.

Xenaki, K. T., Oliveira, S., & vanBergen En Henegouwen, P. M. P. (2017). Antibody or antibody fragments: Implications for molecular imaging and targeted therapy of solid tumors. Frontiers in Immunology, 8, 1287. https://doi.org/10.3389/fimmu.2017.01287

162.

Liu, H., Zhao, Z., Zhang, L., Li, Y., Jain, A., Barve, A., …Cheng, K. (2019). Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. Journal for Immunotherapy of Cancer, 7(1), 270. https://doi.org/10.1186/s40425-019-0705-y

163.

Watson, E. R., Novick, S., Matyskiela, M. E., Chamberlain, P. P., H de la Peña, A., Zhu, J., …Lander, G. C. (2022). Molecular glue CELMoD compounds are regulators of cereblon conformation. Science (New York, N.Y.), 378(6619), 549–553. https://doi.org/10.1126/science.add7574

164.

Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., …Schneider, G. (2022). A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorganic Chemistry, 119, 105505. https://doi.org/10.1016/j.bioorg.2021.105505

165.

Bjorklund, C. C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H., …Thakurta, A. (2020, April). Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. England. https://doi.org/10.1038/s41375-019-0620-8

166.

Gramespacher, J. A., Cotton, A. D., Burroughs, P. W. W., Seiple, I. B., & Wells, J. A. (2022). Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins. ACS Chemical Biology, 17(5), 1259–1268. https://doi.org/10.1021/acschembio.2c00185CrossRefPubMed

Title: Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Authors: Ghazaal Roozitalab
Behnaz Abedi
Saber Imani
Reyhaneh Farghadani
Parham Jabbarzadeh Kaboli
Publication date: 27-02-2024
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Breast Cancer
Breast Cancer
Published in: Cancer and Metastasis Reviews
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-024-10174-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer